中华新闻通讯社/中华时报11月14日曼谷讯（记者袁毅强)摘要： 2025 年 11 月在泰国曼谷举行的「我们的世界」（We Are the World）全球健康创新峰会，在**「中西医融合突破，共建健康丝绸之路」的宏大愿景下圆满落幕。会议不仅宣布成功搭建了全球首个跨学科「共融共建」平台，汇集了顶尖生物科学、AI 专家与中医智慧，集中攻关癌症与慢性病协同治疗。文章将此官方宣言作为起点，随后深入分析峰会现场嘉宾关于创新与监管的观点碰撞，并引入国际监管伦理专家及亚洲 AI 科技界与再生医学领域**的外部趋势分析，以揭示在强烈融合愿景下，跨国医疗创新所面临的系统性挑战。

一、峰会官方介绍与愿景：中西医融合，共建「健康丝绸之路」

2025 年 11 月，为期四天的「我们的世界」全球健康创新峰会在泰国曼谷圆满落幕。本次峰会以**「以融合之力，回应数千万家庭的痛楚」为使命缘起，明确宣告了开创未来医学新纪元**的宏大愿景。

使命与背景： 联合发起人郑志刚博士在致辞中指出，全球每年数千万人死于慢性病，世界迫切需要新的答案。峰会旨在透过古老智慧与前沿科技的创造性融合来回应这一挑战。

核心突破与专家阵容： 峰会核心成就在于搭建了全球首个跨学科的**「共融共建」平台**。多位拥有累计超千年专业经验的全球顶级专家齐聚一堂，通过密集的议程，集中攻关癌症的协同治疗新路径与慢性病管理与全民养生新体系两大核心议题。联合创办人 Michael Chin 先生更以亲身经历证实了「融合」为个体生命带来的奇迹。

全球共识与丝绸之路： 泰国前副总理 Phinij Jarusombat 先生前瞻性地提出，需要建设一条新的**「健康的丝绸之路」**。此宏伟蓝图获得了包括来自二十多个国家领事、中东 Emaar 集团创办人等 300 位全球政商学界 VIP 嘉宾的广泛共鸣，彰显了共建未来健康体系的强大共识。

行动启程： 联合创办人郑志刚博士、Michael Chin 与 Josephine Ko 女士共同表示：「行动胜于一切言语。」峰会现场见证了**「中医药文化协会」及「侠医者联盟」**达成深度战略合作，标志着「融合」从理念走向组织化。大会同时宣布下一届峰会将于 2027 年在中东举行。

二、峰会核心观点碰撞：突破性研究与体制适应的争议

本次峰会的嘉宾争议围绕如何划定医疗创新与监管的边界展开：

创新支持者（峰会嘉宾）： 拿督陈革成教授（Dato’ Prof. Dr. Mike Chan）明确主张，当传统医学无法再提供希望时，创新疗法应该被允许在严格监督下尝试，强调患者有权选择治疗。

学界与监管界（峰会嘉宾）： 泰国前卫生部副部长 Phinij Jarusombat 提出警惕，认为监管与伦理必须同步重视。香港中医药大学研究员 王清博士 则指出，实验性疗法若未经批准，应仅限于临床研究环境，而非市场收费使用。

三、国际监管与伦理的两极辩论：第三方补充论据（外部参考）

峰会关于医疗创新与监管边界的争议，与国际间两大主流观点高度吻合。以下是来自国际患者组织、医学评论者及全球治理专家的外部参考观点，为峰会核心议题提供了更广阔的辩证视角。

一、支持「创新与开放监管」的一方（正方论据）

此方主要诉求是加速患者可及性和体系灵活性，强调在无治疗方案时，生命时间的紧迫性。

国际患者组织领袖的声音，如 APARDO 和 Rare Diseases International 的 Durhane Wong-Rieger 博士，从罕病患者视角指出，监管应兼顾安全与可及性。她认为，对于无替代治疗选项的患者，应允许在严格监督下使用实验性疗法，以避免因程序延误而错失机会，强调**「延误就是伤害」。同时，数位健康专家 Paul Wicks 博士 倡议，创新疗法不必等到所有大型试验完成，应采用数字化工具与患者报告结果（PROs）加速风险评估，支持监管采纳「动态证据模式」。此外，多场东南亚罕病峰会的共识亦强调，在严格监测机制存在的前提下，应赋予某些晚期患者早期使用实验性产品的选择权**。

二、主张「审慎监管与患者保护」的一方（反方论据）

此方主要诉求是保障患者安全和证据的严谨性，警惕商业利益在伦理灰色地带中扩张。

英国医生、BMJ 评论作者 Margaret McCartney 博士作为证据医学倡议者，指出任何收费的治疗必须有足够证据。她批评，若商业机构在缺乏有效证据的情况下推广高价疗法，将使脆弱患者群体承担不必要风险。此外，全球健康治理专家 Ilona Kickbusch 则强调跨国医疗活动必须建立统一伦理与监管框架，警示若缺乏此框架，易产生监管套利（Regulatory Arbitrage），最终将损害患者安全。这一立场也与WHO 和 FDA 的官方立场一致：两大机构均提醒应避免**「未证实疗法的商业化」**，且 FDA 明确规定「同情使用」（Expanded Access）不得商业化收费，仅能收取成本。

四、亚洲 AI 科技界的外部趋势分析：创新实践与体制挑战

峰会的论辩引发了对亚洲 AI 医疗和再生医学领域实践的深度反思。来自亚洲不同领域的专家意见，为峰会的核心争议提供了强有力的外部论证。

1. 科技界的呼吁：AI 速度与动态监管

亚洲科技界普遍认为，现有监管体系已难以跟上 AI 赋能的创新速度。

台湾科技界代表趋势： 台湾长佳智能的 李友铮博士 观点指出，AI 在精准医疗和药物研发上的速度与能力已远超现有审批制度，因此，体制必须做出调整。他强调 AI 的演化正走向**「具身式 AI」（Embodied AI），呼吁监管单位采纳「动态监管机制」（dynamic regulation）**，以避免创新被过度延迟。

泰国在地应用趋势： 泰国 AI 健康先驱 Dr. Supiya Charoensiriwath 博士 的实践则聚焦于 AI 在公共卫生和预防医学的在地化落地。同时，泰国企业如 CARIVA 和 Looloo Health 的行动，也体现了 AI 在优化医院流程和远程诊断可及性上的巨大价值。

2. 再生医学的实践案例：刘保池团队与 AI 潜力

中国再生医学案例： 来自上海公共卫生的刘保池博导团队提供的治疗方案，利用患者自身的**自体骨髓干细胞（ABMI/ABMNCs）**修复受损的肝脏和/或胰腺。此案例体现了再生医学在修复肝功能和改善糖尿病方面的潜力。

3. 癌症与长寿研究突破：AI 加速新药与精准治疗

精准治疗加速： AI 在此处扮演**「精准定位」**的角色，能整合患者的基因数据和病史，加速识别和锁定新的治疗靶点，实现个体化治疗方案。

新药研发优化： 在长寿医学中，AI 通过模拟和分析大量的化合物结构，加速药物发现和优化给药方案，例如预测**雷帕霉素（Rapamycin）**等抗衰老药物的最低有效剂量，降低研发成本和试验风险。

五、深度分析：地缘政治与跨国伦理挑战

跨国医疗的伦理黑洞： 峰会的愿景和现实之间存在巨大的监管鸿沟。当创新疗法从研究走向商业应用时，特别是针对境外患者，伦理监督和患者保护的界线模糊。若缺乏统一标准，「同情使用」容易被包装成「付费治疗」，使处于弱势的患者群体暴露于未经充分证实的疗法的风险之下。

知情同意的真实性困境： 在跨国医疗中，信息不对等性被极度放大。患者往往在**「最后希望」的压力下，难以做出真正的知情同意**（Informed Consent）。监管机构必须担保，无论在哪里提供治疗，患者对风险、费用、替代选项和证据基础都拥有完整透明的知情权。

地缘政治的影响： 峰会体现了亚洲在生物健康领域的强烈崛起意图，试图将香港/亚洲定位为下一代医疗中心。然而，缺乏与西方（如 FDA, EMA）同步的严格且统一的监管框架，可能导致亚洲部分地区成为**「监管避风港」（Regulatory Haven）**，这将不利于长期国际合作和创新成果的可信度。

六、结语：迈向伦理共识的转译通道

「我们的世界」峰会成功地描绘了一幅中西医融合、科技赋能的宏伟蓝图。然而，从蓝图到真实世界的实践，必须穿越监管与伦理的雷区。未来的「健康丝绸之路」要行稳致远，不仅需要 AI 和再生医学的技术突破，更需要强大的跨国监管协作机制和对患者自主权与安全的坚定承诺。这场辩论的最终意义，在于找到一条将创新成果伦理化转译的通道，确保医疗的进步，真正服务于人类的共同健康福祉。

We Are the World Bangkok 2025: Analysis of Innovation Spectrum, Regulatory Boundaries, and Patient Empowerment International Summit Outcomes

ChinaTimes  Nov. 14, 2025, Bangkok（Revision）  By  YIQIANG YUAN

Summary: The "We Are the World" Global Health Innovation Summit, held in Bangkok in November 2025, concluded under the grand vision of "Achieving Breakthroughs in TCM/Western Medicine Fusion to Build a Healthy Silk Road." The conference announced the successful establishment of the world's first interdisciplinary "Co-Creation and Co-Integration" platform, bringing together top bioscience, AI experts, and traditional Chinese medicine (TCM) wisdom to tackle cancer and chronic disease through synergistic treatment. This analysis takes the official declaration as its starting point, moving to an in-depth exploration of the on-site guest debate on innovation and regulation, supplemented by international regulatory ethics experts and external trend analysis from the Asian AI technology and regenerative medicine sectors, revealing the systemic challenges faced by cross-border medical innovation amidst a strong vision of integration.

I. Summit Official Introduction & Vision: TCM/Western Medicine Fusion for a "Healthy Silk Road"

The four-day "We Are the World" Global Health Innovation Summit concluded successfully in Bangkok in November 2025. The summit’s mission was rooted in "Responding to the Suffering of Tens of Millions of Families through the Power of Integration," clearly declaring a grand vision for pioneering a new era of future medicine.

Mission and Background: Co-Initiator Dr. Adrian Cheng noted in his opening speech that millions globally die annually from chronic diseases, emphasizing the world's urgent need for a new answer. The summit aimed to address this challenge through the creative fusion of ancient wisdom and cutting-edge technology.

Core Breakthroughs and Expert Lineup: The summit's core achievement was the establishment of the world's first interdisciplinary "Co-Creation and Co-Integration" platform. Multiple top global experts with over a thousand years of combined professional experience gathered to focus on two core issues through intensive agendas: Cancer's Synergistic Treatment Pathways and a New System for Chronic Disease Management and Public Wellness. Co-Founder Michael Chin also affirmed the miracles brought by "integration" to individual lives through his personal experience.

Global Consensus and the Silk Road: Former Thai Deputy Prime Minister Mr. Phinij Jarusombat proactively proposed the need to build a new "Healthy Silk Road." This vision resonated widely among the 300 VIP guests from global political, business, and academic sectors, including consuls from over twenty countries, signifying a strong consensus for building a future health system.

The Launch of Action: Co-Initiators Dr. Adrian Cheng, Michael Chin, and Josephine Ko jointly stated: "Action speaks louder than words." The summit witnessed strategic collaborations with the "Association for the Promotion of Chinese Medical Culture" and the "Alliance of Righteous Doctors," marking the transition of "integration" from a concept to organized action. The next global summit was announced to be held in the Middle East in 2027.

II. Core Summit Debate: The Controversy Over Breakthrough Research and System Adaptation

The debate among the summit's guests focused on defining the boundaries between medical innovation and regulation:

Innovation Advocates (Summit Guests): Dato’ Prof. Dr. Mike Chan asserted that when conventional medicine can no longer offer hope, innovative therapies should be permitted under strict supervision, emphasizing the patient's right to choose treatment.

Academia and Regulatory Bodies (Summit Guests): Phinij Jarusombat cautioned that regulation and ethics must be equally prioritized. Dr. Wang Qing, a researcher at a Hong Kong Traditional Chinese Medicine University, stated that experimental therapies, if unapproved, must be restricted exclusively to the clinical research environment, not utilized for commercial, fee-for-service purposes.

III. The International Regulatory and Ethical Divide: Third-Party Supplement (External Reference)

The controversy over innovation and regulatory boundaries at the summit highly aligns with two major international viewpoints. Below are external reference viewpoints from international patient organizations, medical reviewers, and global governance experts, providing a broader, dialectical perspective on the summit's core issues.

I. Supporting "Innovation and Open Regulation" (Pro-Innovation Arguments)

This side primarily advocates for accelerated patient accessibility and system flexibility, emphasizing the urgency of life when no treatment options are available.

The voice of international patient organization leaders, such as Dr. Durhane Wong-Rieger (APARDO and Rare Diseases International), speaking from the rare disease perspective, noted that regulation should balance safety and accessibility. She argues that for patients with no alternative treatment options, experimental therapies should be permitted under strict supervision to prevent them from missing opportunities due to procedural delays, emphasizing that "delay is harm." Furthermore, digital health expert Dr. Paul Wicks advocates that innovative therapies need not wait for the completion of all large-scale trials, urging the adoption of digital tools and Patient-Reported Outcomes (PROs) to accelerate risk assessment and supporting the regulatory adoption of a "Dynamic Evidence Model." Additionally, the consensus from several Southeast Asia Rare Disease Summits emphasizes that under strict monitoring mechanisms, certain late-stage patients should be granted the option for early access to experimental products.

II. Advocating for "Prudent Regulation and Patient Protection" (Pro-Safety Arguments)

This side primarily advocates for patient safety and the rigor of evidence, warning against the expansion of commercial interests in ethical grey areas.

Dr. Margaret McCartney, a UK physician and BMJ review author, as an advocate for evidence-based medicine, stated that any fee-based treatment must be backed by adequate evidence. She criticizes that if commercial entities promote high-cost therapies without sufficient evidence, vulnerable patient groups will assume unnecessary risks. Furthermore, Ilona Kickbusch, a global health governance expert, emphasizes that cross-border medical activities must establish a unified ethical and regulatory framework, warning that a lack thereof can lead to Regulatory Arbitrage, ultimately compromising patient safety. This stance is consistent with the official positions of the WHO and the FDA: both agencies caution against the "commercialization of unproven therapies," and the FDA explicitly stipulates that "Expanded Access" (compassionate use) cannot be commercially charged, only cost-recovery fees can be collected.

IV. External Analysis of Asian AI Technology Trends: Innovation Practice and System Challenges

The summit's debate prompted a deeper reflection on practices within the Asian AI healthcare and regenerative medicine sectors. Expert opinions from different Asian regions provide robust external arguments supporting the core controversy.

1. The Technology Sector’s Call: AI Speed and Dynamic Regulation

The Asian technology community generally argues that existing regulatory systems are struggling to keep pace with AI-enabled innovation.

Taiwan Technology Representative Trend: The viewpoint of Dr. Li You-Cheng of Chang Gung AI in Taiwan highlights that AI’s speed and capability in personalized medicine and drug discovery far surpass existing approval systems; therefore, the system must adapt. He emphasized that AI is evolving toward "Embodied AI," calling for regulatory bodies to adopt a "Dynamic Regulation" mechanism to prevent innovation from being unduly delayed.

Thai Local Application Trend: The work of Thai AI health pioneer Dr. Supiya Charoensiriwath focuses on the localized implementation of AI in public health and preventive medicine. Additionally, the actions of Thai companies like CARIVA and Looloo Health demonstrate the huge value of AI in optimizing hospital workflows and remote diagnosis accessibility.

2. Regenerative Medicine Case Study: Liu Baochi Team and AI Potential

China Regenerative Medicine Case: The treatment approach by Professor Baochi Liu’s team from Shanghai Public Health—utilizing the patient’s own Autologous Bone Marrow Stem Cells (ABMI/ABMNCs) to repair the damaged liver and/or pancreas—provides a specific academic case study of regenerative potential.

Technology Sector Analysis: Technology representatives observed that high-precision regenerative therapies like Professor Liu's method are highly dependent on AI for processing and predicting complex biological data. AI can optimize the in vitro stem cell differentiation process, predict efficacy, and assist in the precise planning of micro-invasive interventions.

3. Cancer and Longevity Breakthroughs: AI Accelerates New Drugs and Precision

Precision Treatment Acceleration: AI serves as the "precision locator," integrating patient genomic and historical data to accelerate the identification of new therapeutic targets, enabling individualized treatment plans.

New Drug Development Optimization: In longevity medicine, AI accelerates drug discovery and optimizes dosing regimens by simulating and analyzing compound structures, such as predicting the optimal minimum effective dose for anti-aging drugs like Rapamycin, thereby reducing R&D costs and trial risks.

V. Deep Analysis: Geopolitics and Cross-Border Ethical Challenges

The Ethical Black Hole of Cross-Border Healthcare: A significant regulatory gap exists between the summit's vision and reality. When innovative therapies move from research to commercial application, especially for foreign patients, the boundary of ethical oversight and patient protection blurs. Without uniform standards, "compassionate use" can easily be disguised as "fee-for-service treatment," exposing vulnerable patient groups to the risks of insufficiently proven therapies.

The Authenticity Dilemma of Informed Consent: Information asymmetry is highly amplified in cross-border medical care. Patients, often under the pressure of "last hope," struggle to provide genuine Informed Consent. Regulatory bodies must guarantee that, regardless of where treatment is provided, patients have full and transparent knowledge of the risks, costs, alternative options, and evidence base.

The Impact of Geopolitics: The summit reflects Asia's strong intention to rise in the biohealth sector, aiming to position Hong Kong/Asia as the next generation's medical hub. However, a lack of strict and unified regulatory frameworks synchronized with the West (e.g., FDA, EMA) may lead to certain parts of Asia becoming a "Regulatory Haven," which would be detrimental to long-term international collaboration and the credibility of innovative achievements.

VI. Conclusion: Towards a Translational Pathway of Ethical Consensus

The "We Are the World" Summit successfully painted a magnificent blueprint of TCM-Western medicine integration, technologically empowered. However, the path from blueprint to real-world practice must navigate the minefield of regulation and ethics. For the future "Healthy Silk Road" to proceed stably, it requires not only technological breakthroughs in AI and regenerative medicine but also robust cross-border regulatory collaboration mechanisms and an unwavering commitment to patient autonomy and safety. The ultimate significance of this debate lies in finding a channel to ethically translate innovative achievements, ensuring that medical progress truly serves the common health and well-being of humanity.